Novartis Digital Biomarker Innovation Challenge

Digital health is shaping the future of the medicine, and digital biomarkers will likely become part of common disease management. To foster this field, Novartis has defined several high-impact research themes related to Digital Biomarkers/Digital Endpoints. This program is calling for novel digital biomarker solutions to accelerate their adoptions into early stage clinical studies. Novartis Taiwan and ETBA have teamed up to promote this challenge to discover potential collaboration.

Designed by macrovector / Freepik

What are we looking for?

Digital Biomarkers in the seven research areas

  • Cognition and attention
  • Fatigue
  • Sleep
  • Depression and mood
  • Pain
  • Mobility
  • Digital imaging of skin

Who is eligible for this challenge?

Companies, start-ups, and academic research groups with the state-of-art technology in the above mentioned research areas are all welcome to apply!

What could you expect?

A collaboration opportunity with a global Pharma research team. Budgets is available in advanced stages.

The procedure:

  • Step 1: The primary screening will be conducted jointly by ETBA and Novartis Taiwan.
  • Step 2: The initial assessment will be executed by the Novartis Institutes for BioMedical Research (NIBR), including workshops and device evaluation.
  • Step 3: For promising solutions, formal collaboration will be established and the solution will be deployed in Novartis clinical studies.


November 30, 2020, at 11:00 CET / 18:00 TPE time

To learn more: